Benzochloroporphyrin derivative photosensitizer-mediated photodynamic therapy for Ewing sarcoma.

Mengxiong Sun,Chenghao Zhou,Hui Zeng,Fei Yin,Zhuoying Wang,Jianzhong Yao,Yingqi Hua,Zhengdong Cai
DOI: https://doi.org/10.1016/j.jphotobiol.2016.03.059
2016-01-01
Abstract:In this study, we evaluated the photodynamic efficacy of a new photosensitizer, benzochloroporphyrin derivative 18 (BCPD-18), in Ewing sarcoma. We found that BCPD-18 decreased the viability of TC-71 cells irradiated by 670nm laser in a concentration dependent manner. We also observed cells undergoing apoptosis as well as cell cycle arrest at the G2M phase after BCPD-18-mediated photodynamic therapy (BCPD-PDT). In addition, in vivo study (subcutaneous and orthotopic models) showed that BCPD-PDT reduced tumor size, tumor weight and tumor-bearing leg weight. After PDT, apoptosis was shown in vivo. Bax expression was increased, and Bcl-2 expression was decreased. This study provides evidence that BCPD-18 could probably be a useful photosensitizer in PDT for Ewing sarcoma.
What problem does this paper attempt to address?